semaj83/ctmatch_classification huggingface dataset:
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 3.0-999.0,  Mycobacterium Ulcerans Disease Buruli Ulcer Patients with a clinical picture of Buruli ulcer disease in the districts covered by the Buruli ulcer centers in Lalo and Allada, Benin, will be included at start of antibiotic treatment All stages of the disease will be included. Only patients with confirmed disease by direct microscopy following acid-fast staining or PCR will be included  Patients not on the standard treatment of eight weeks of rifampicin and streptomycin for any reason, will be excluded from this study Treatment with macrolide or quinolone antibiotics, or antituberculous medication, or immune-modulatory drugs including corticosteroids within the previous one month Patients not compliant with the antibiotic therapy will be excluded as well. Non-compliance is defined as the use of < 70 % of the prescribed antibiotics Patients with a contraindication for general anaesthesia are not able to participate Pregnancy Osteomyelitis Lesion close to the eye, with preferred standard treatment to wait for effect antibiotic treatment on extent surgery The BUFLS (Buruli ulcer functional limitation score) cannot be applied to children below three years and therefore will not participate Patients reporting to refuse surgery at any point in the intended treatment, cannot be included Any situation or condition which may compromise ability to comply with the trial procedures
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Varicose Ulcer Patient over 18 years old who has provided his/her written informed consent Patient who can be monitored by the same investigation team throughout the duration of the study Patient who agrees to wear effective venous compression every day, associated with the trial dressing Leg ulcer with a distal Ankle Brachial Pressure Index (ABPI) not less than 0.7 and not more than 1.3 Ulcer with a minimum area of 3 cm2 and a maximum area of 30 cm2 Ulcer duration between 3 and 36 months Ulcer where the surface area is 70% or more covered by fibrinous tissue Ulcer at least 3 cm away from any other lesion Ulcer moderately or strongly exudative justifying the use of an absorbent dressing  Female patient of child-bearing potential who has no effective means of contraception Patient who is pregnant or breastfeeding Patient taking part in another therapeutic trial Patient with hypersensitivity to one of the components of the trial dressing or a known allergy to carboxymethylcellulose (hydrocolloid) Patient with a serious general pathological condition who, it may be feared, might discontinue participation in the trial before the six weeks of treatment Patient with an evolving neoplastic condition, treated by radiotherapy, chemotherapy or hormone therapy Patient with a systemic infection not controlled by suitable antibiotic treatment Patient who, during the 3 months before presented a deep vein thrombosis Ulcer where its surface is totally or partially covered by black necrotic plaque Ulcer which is clinically infected
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Evaluate Surgical, Medical and Pharmacological Factors Influence on Wound Healing Following Primary Arthroplasty Surgery All patients receiving primary hip or knee arthroplasty at Hvidovre Hospital from january 2012 to january 2014  Not willing to participate Drop out at 3 week follow up
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 20.0-62.0,  Ischemic Ulcer Ischemic lower limb based on TASK guide line Rutherford score:2,3 ABI<0.6 Absolute ankle pressure < 60 mmHg Both gender Age:20-62years  EF<30% Cr>2 HbA1c>8% Bone marrow disorders:leukemia Cognitive disorders Infections MI with ST elevation during last month Malignancy Immunologic or rheumatologic disorders
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Diabetic Foot Ulcer Adult diabetic foot syndrome subjects over 18 years of age of any sex All stages of diabetic foot syndrome including Wagner stage 5 Mid-foot gangrene only after appropriate surgical treatment Patients suffering from type 1 or type 2 diabetes mellitus with diabetic foot syndrome Stable metabolic and pharmacological control at recruitment and during the trial period Adequate perfusion of lower limb as measured by HHD and confirmed by APSV  Non-diabetic foot ulceration (traumatic, thermal ulceration etc) Diabetic foot syndrome graded 5 on Wagner's scale hind foot gangrene only Any pathological state or disease which can affect the development and outcomes of diabetic foot syndrome such as liver cell failure and renal failure Severe limb ischemia (by clinical assessment and HHD) unless re-vascularized Presence of slough or sequestrum unless debrided Hemoglobin less than 8 g/dl unless corrected Those receiving NSAIDs, steroids or anti-mitotic drugs Septicemia patients requiring urgent amputation
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Patients with insufficiently controlled type 1 or type 2 diabetes mellitus under their previous therapy
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 40.0-75.0,  Foot Ulcer, Diabetic between ages 40 and 75 history of diabetic neuropathic plantar ulcer (test subjects) no history of diabetes (control subjects) no peripheral sensory neuropathy (control subjects)  amputation or surgery on right Great Toe
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Osteoarthritis, Hip Joint Deformities, Acquired Hip Dislocation, Congenital Osteonecrosis Arthritis, Rheumatoid Undergoing primary unilateral total hip arthroplasty via the anterior supine intermuscular approach Patient is willing and able to complete all follow-up visits at 6 weeks and 1 year  Patients with pre-existing known coagulopathy Patients on chronic Coumadin (Warfarin) therapy Patients receiving erythropoietin therapy for anemia
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Ottawa Score Adenoma patients undergoing colonoscopy  disturbance of water and electrolyte history of colorectal surgery severe colonic stricture or obstructing tumor known or suspected bowel obstruction or perforation toxic colitis or megacolon dysphagia compromised swallowing reflex or mental status significant gastroparesis or gastric outlet obstruction or ileus severe chronic renal failure (creatinine clearance ＜30 mL/minute) severe congestive heart failure (New York Heart Association class III or IV)
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus Diabetic Neuropathic Foot Ulcer More of 18 years old man or woman Type 1 or 2 Diabetes mellitus A new plantar ulcer of the fore foot or the toes GRADE 1A or 2 A of the University of Texas Classification Neuropathy assessed by absence of sensation in 10g monofilament test  Severe angiopathy (Grade 3 of the PEDIS classification) Osteomyelitis or cellulitis of the foot Transmetatarsal amputation Other study in course Immunosuppressive drugs, antibiotic therapy Hepatic insufficiency No possibility to follow the patients every 14 days No state health insurance Pregnancy
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Ulcer Skin Ulcer Leg Ulcer Diabetic Foot Patient is 18 years old or older Patient has a diagnosis of arterial, diabetic foot, venous insufficiency, or pressure ulcer or surgical and traumatic wound Patient's target study ulcer/wound is a lower extremity full thickness ulcer/wound not involving tendon, capsule, or bone Patient's target study ulcer/wound and is ≥1.0 cm2 and ≤ 10.0 cm2 in size at the day of initial consult Study ulcer/wound has been present for greater than 6 weeks prior to initial consult Patients with Charcot foot deformities can be entered so long as the Charcot disease is not active, and the ulcer can be offloaded by an orthotic device The patient has adequate circulation to the lower extremity as evidenced by an ABI (measured by Doppler) of ≥ 0.7. If the patient has non-compressible leg arteries, as documented by an ABI >1.3, then the patient must have a Toe-Brachial Index be > 0.6, or a toe pressure >50 mm Hg Patient must have adequate in-home support to comply with all protocol-mandated visits and procedures, offloading or pressure redistribution as required, and proper application of study products and wound care regimen Patient or his/her legal representative has read and signed the Institutional Review Board-approved Informed Consent form before Screening  An ulcer/wound that is ≥10.0 cm2 and ≤ 1.0 cm2 in size at the day of initial consult is not eligible for this study Patient has clinical evidence of gangrene or infection on any part of the affected foot The patient is judged by the investigator or study staff to be unable or unlikely to comply with daily wound care instructions, or study visits Patient has clinical evidence of active sepsis or invasive infection (e.g., cellulitis, osteomyelitis) Patient has muscle, tendon, or bone exposure in any ulcer bed Patient has known sensitivity or allergy to any component of the study product Olivamine10 Patient has one or more medical condition(s), including renal, hepatic, hematologic, neurologic, or immune disease that in the opinion of the Investigator would make the patient an inappropriate candidate for this wound healing study Patient has a malignant disease (other than squamous or basal cell carcinoma of the skin) not in remission for five years or more
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Peripheral Artery Disease Without Critical Limb Ischemia Patients need to be at least 18 years old Patients have to be admitted to the university hospitals of Geneva for a non-healing lower limb ulcer Eligible patients are those presenting with non-healing lower limb ulcers for more than 3 months Patients will be hospitalized in the Dermatology inpatient clinic Patients had to benefit from at least one thin skin autograft at the ulcer level in the past or during the index hospitalization Before in the study, patients must undergo complete angiological diagnostic work-up including A baseline ABI, toe pressure and tcPO2 measurements A non-invasive arterial imaging including an angio-CT scan or an angio-MRI The non-invasive arterial work-up must revel mild to moderate PAD, without any or sign of CLI (see flow-chart) Ankle pressure ≥ 50 mmHg  Patients who refused to give their written informed consent Patients, in whom the angiological work-up shows the presence of a CLI, mandating a revascularization procedure attempt (i.e. ankle pressure < 50mmHg, toe pressure < 30mmHg, tcPO2 < 20mmHg) (see particular situation n°2) Patients who do not present with peripheral artery disease (i.e., ABI > 0.9 < 1.3, TP > 100mmHg, tcPO2 > 40mmHg) Patients in whom the angiological-dermatological work-up shows the presence of another reversible cause of the non-healing ulcer Special attention will be given to the presence of a treatable venous insufficiency (e.g. compression stocking, varices stripping), an underlying inflammatory/infectious process (treatable with antibiotics or topic-systemic antiinflammatory medications) or other reversible mechanical factors (unadapted shoes, etc.) Patients without any significant lesion of the arterial tree (ilio-femoro-popliteal and infra-popliteal) In case there will be a single BTK vessel disease not perfusing the ulcer area (e.g. pre-tibial ulcer with a significant stenosis of the posterior tibial artery which does not perfuse the ulcer region), the patient will not be included in the study because any significant ulcer improvement would be expected from this non-target vessel revascularization Patients in whom the scheduled revascularization procedure will be judged too risky for the patient's safety Chronic kidney failure (= Creatinin Clearance < 20ml/min) with an increased risk of contrast induced nephropathy
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 5.0-20.0,  Neurogenic Bladder Diagnosis of spina bifida and neurogenic bladder Performing clean intermittent catheterization (CIC) Taking 0.3-0.4 mg/kg/day of oxybutynin for a poorly compliant bladder Has not had previous bladder surgery Has had a urodynamic or videourodynamic study done within the last 6 months Upper motor neuron (UMN) type bladder demonstrated on last urodynamic study Urodynamic study (UDS) showing either detrusor leak point pressure >40cm H2O; 30cm below capacity <60% of total bladder capacity, 20 cm capacity <70% of bladder capacity Able and willing to complete CIC Diaries and Quality of Life Questionnaires Consent and assent given to participate in trial  History of lung disease, recurrent aspiration or severe neurological impairment which may increase risk of Botox toxicity or anesthesia Positive urine culture Known allergy to Botox
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 10.0-17.0,  Type 1 Diabetes Mellitus English-speaking patients to 18 years diagnosed with type 1 diabetes for at least 12 months poor diabetes control as defined by having a hemoglobin A1c value > 8%  type 2 diabetes developmental delay current participation in another study that may impact glycemic control
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Detrusor Function, Overactive Diagnosis of overactive bladder as a result of neurogenic condition, for example following spinal cord injury, multiple sclerosis (slowly worsening disorder of the central nervous system that causes symptoms such as weakness, incoordination, numbness, problems talking and problems seeing), Parkinson's disease (a progressive disorder of the central nervous system, seen usually in older persons, in which there is slow movement [due to muscle weakness], trembling and sweating), or cerebrovascular accidents (CVAs stroke-sudden loss of blood supply to brain) Women must not be pregnant and be of either non-childbearing potential or is using adequate means of birth control Overactive bladder symptoms and/or has urge incontinence episodes Must have normal results on urine culture tests and on urinalysis ECOG (Eastern Cooperative Oncology Group) performance status score of less than or equal to 3  Participants with 1 or more treatable or conditions, other than neurogenic bladder dysfunction, that may cause urinary incontinence or urgency Any medical or unstable condition that precludes their participation in the study or may confound the outcome of the study (participants with or at risk for urinary retention, gastric retention or uncontrolled narrow angle; heart failure or kidney failure; diabetes mellitus; abnormal muscle weakness [myasthenia gravis]; paralysis or inactivity in the intestines that prevents material moving through the gut [intestinal atony or paralytic ileus]; severe inflammation of the bowel [ulcerative colitis] sudden expansion of the large intestine seen in advanced ulcerative colitis or Crohn's disease [toxic megacolon]; history of major lower urinary tract surgery [transurethral resection will be excluded]) Hypersensitivity to the investigational drug or any of its ingredients (eg, lactose) Pregnant or breast feeding female Significant bacteriuria (presence of bacteria in the urine) or pyuria (presence of white blood cells) in the urine
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 45.0-65.0,  Fibromyalgia fibromyalgia diagnosed by physical examination of pain sensitivity, by Dolorimeter and finger pressure  any past hyperbaric oxygen therapy chest x-ray pathology which does not allow the income into the hyperbaric chamber middle ear problems patients, who cannot "pump", equals middle ear pressure, effectively patients who suffer from claustrophobia inability or Refusing to sign the Informed Consent Form
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-69.0,  Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Glycosylated haemoglobin (HbA1c) below or equal to 10 procent based on central laboratory results Specific for subject with type 1 diabetes Diagnosed with type 1 diabetes mellitus and treated with insulin for at least 12 months prior to screening Body Mass Index (BMI) between 18.0 and 27.0 kg/m^2 (both inclusive) Specific for subject with type 2 diabetes Diagnosed with type 2 diabetes mellitus for at least 12 months prior to screening Treated with insulin for the past 3 months prior to screening Body Mass Index (BMI) between 22.0 and 35.0 kg/ m^2 (both inclusive)  Subject with a history of significant multiple drug allergies or with a known allergy or suspected allergy to the trial product or any medicine chemically related to the trial product,as judged by the Investigator Subject with a history of or presence of cancer Any condition that the Investigator and/or Sponsor feels would interfere with study Specific for subject with type 2 diabetes Therapy with oral antidiabetic drugs within the past 3 months prior to screening
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-92.0,  Bowen's Disease Korean patients aged ≥ 18 years who had biopsy-confirmed BD lesions on the lower extremities  porphyria known allergies to the MAL cream or lidocaine pregnancy lactation any active systemic infectious disease immunosuppressive treatment personal history of malignant melanoma tendency towards melasma or keloid formation prior treatment of the lesions within 4 weeks, and any indication of poor compliance